Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Exelixis, Inc. (NASDAQ:EXEL) are both Healthcare companies that recently hit new low. Naturally, this has caught the attention of the investment community. But which is the better investment? To answer this question, we will compare the two companies across various metrics including growth, profitability, risk, return, dividends, and valuation.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) operates in the Biotechnology segment of the Healthcare sector. The company has grown sales at a 61.30% annual rate over the past five years, putting it in the high growth category. REGN has a net profit margin of 22.10% and is more profitable than the average company in the Biotechnology industry. In terms of efficiency, REGN has an asset turnover ratio of 0.7. This figure represents the amount of revenue a company generates per dollar of assets. REGN’s financial leverage ratio is 0.47, which indicates that the company’s asset base is primarily funded by equity capital. Company’s return on equity, which is really just the product of the company’s profit margin, asset turnover, and financial leverage ratios, is 23.90%, which is better than the Biotechnology industry average ROE.Stock’s free cash flow yield, which represents the amount of cash available to investors before dividends, expressed as a percentage of the stock price, is -0.18. Company trades at a P/E ratio of 41.00, and is less expensive than the average stock in the Biotechnology industry. The average investment recommendation for REGN, taken from a group of Wall Street Analysts, is 2.30, or a buy.Over the past three months, Regeneron Pharmaceuticals, Inc. insiders have been net buyers, dumping a net of -10,815 shares. This implies that insiders have been feeling relatively bearish about the outlook for REGN. Insider activity and sentiment signals are important to monitor because they can shed light on how “risky” a stock is perceived to be at it’s current valuation. Knowing this, it makes sense to look at beta, a measure of market risk. REGN has a beta of 1.60 and therefore an above average level of market volatility.
     (adsbygoogle = window.adsbygoogle || []).push({});
Exelixis, Inc. (NASDAQ:EXEL) operates in the Biotechnology segment of the Healthcare sector. EXEL has increased sales at a -7.90% CAGR over the past five years, and is considered a low growth stock. The company has a net profit margin of 36.80% and is more profitable than the average Biotechnology player. EXEL’s asset turnover ratio is 0.71 and the company has financial leverage of 1.55. EXEL’s return on equity of 101.20% is better than the Biotechnology industry average.Stock has a payout ratio of 0.00%. According to this ratio, EXEL should be able to continue making payouts at these levels. The company trades at a free cash flow yield of 0.46 and has a P/E of 53.25. Compared to the average company in the 135.21 space, EXEL is relatively cheap. The average analyst recommendation for EXEL is 2.30, or a buy.Exelixis, Inc. insiders have sold a net of -525,442 shares during the past three months, which implies that the company’s top executives have been feeling bearish about the stock’s outlook. Finally, EXEL’s beta of 1.88 indicates that the stock has an above average level of market risk.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) scores higher than Exelixis, Inc. (NASDAQ:EXEL) on 5 of the 13 measures compared between the two companies. REGN has the better fundamentals, scoring higher on growth and leverage metrics. REGN has better insider activity and sentiment signals.



(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});


Economy and Money Authors gives investors their free and unbiased view of Financial Markets and on what happening in Stock Market. Our team certainly analyze tons of Stocks every day and provide their fair opinion on them. We are always looking over financial statements, company’s earning, analyst upgrades/downgrades, joint ventures and balance sheets to keep our reader up to date.